drugset / Trial / NCT04667949

Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients

NCT04667949

Phase 4 Completed 98 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study was to assess the efficacy and safety of 0.5mg Fingolimod (Gilenya) in Chinese patients with relapsing multiple sclerosis (RMS)

Timeline

Start
2021-02-20
Primary completion
2025-03-25
Completion
2025-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Fingolimod Small molecule 0.5 mg Oral

Indications